Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Sourced and formulated in the United States, Ameriflor Calm is derived from plants grown on regenerative organic certified farms and is manufactured at a site that uses 100% renewable electricity
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
Subscribe To Our Newsletter & Stay Updated